Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ISB 1302

Drug Profile

ISB 1302

Alternative Names: Anti-HER2-anti-CD3-antibody - Glenmark; GBR-1302; HBM-9302; ISB-1302

Latest Information Update: 26 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glenmark Pharmaceuticals S.A.
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer
  • Phase I Gastric cancer; Solid tumours

Most Recent Events

  • 15 Oct 2019 Ichnos Sciences is a spin off from Glenmark Holdings SA
  • 12 Sep 2019 Phase-I clinical trials in Gastric cancer in USA (IV) (Harbour BioMed pipeline, September 2019)
  • 27 Aug 2019 Phase-I/II clinical trials in Breast cancer (Monotherapy, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT03983395)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top